Ashley Rawls, MD
Neurology · Gainesville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 8
Offices
8 locations · Florida Clinical Practice Association Inc · 1,886 clinicians in this group
Looking this up.
Hospitals listed: Uf Health Shands Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rawls’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Uf Health Shands HospitalGainesville, FLAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of UF Health, which runs 5 hospitalsHome of University of Florida Health Cancer Institute, a National Cancer Institute designated cancer centrePatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2 (1.28 to 2.73) · 3,798 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.03 (1.95 to 4.1) · 2,563 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 8.67 (6.52 to 10.82) · 2,469 cases, Jul 2022 – Jun 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 113.22 (85.47 to 140.97) · 430 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.14 (0 to 0.48) · 15,608 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.174, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.423, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.324, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.229, Oct 2024 – Sep 2025
See every measure and the patient survey for Uf Health Shands Hospital
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2 (1.28 to 2.73) · 3,798 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.03 (1.95 to 4.1) · 2,563 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.67 (6.52 to 10.82) · 2,469 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 113.22 (85.47 to 140.97) · 430 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.48) · 15,608 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.174 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.423 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.324 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.229 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.1 (0.93 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.5 · 273 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 220 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 643 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 916 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.9 · 522 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.5 · 7,753 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0.04 to 0.37) · 16,288 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.04 to 0.36) · 17,469 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.37 (3.07 to 5.67) · 5,167 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.6 (1.62 to 3.59) · 4,663 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.6 (6.5 to 12.71) · 2,494 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.2 (0.99 to 3.42) · 1,249 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 163 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 1.173 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.56 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 338 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 1,281 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.4 · 226 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.1 · 768 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 41.3 · 1,023 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 1,425 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.2 to 7.7) · 461 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (9.8 to 15.2) · 461 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.6 · 82 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 713 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.8 to 18.5) · 2,297 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,608 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,034 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$227,044
Medicare paid this office $227,044 for 264 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Botox | 64 | $157,807 | None |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 34 | $7,658 | $132 |
| Muscle electrical test | 55 | $5,822 | $55 |
| New patient visit (60+ min) | 36 | $5,689 | $158 |
| Face injection for nerve paralysis | 15 | $5,282 | $143 |
See all 12 services
| Botox | 64 | $157,807 | None |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 34 | $7,658 | $132 |
| Muscle electrical test | 55 | $5,822 | $55 |
| New patient visit (60+ min) | 36 | $5,689 | $158 |
| Face injection for nerve paralysis | 15 | $5,282 | $143 |
| Return visit (30+ min) | 66 | $5,243 | $74 |
| Long return visit (40+ min) | 36 | $5,129 | $128 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 15 | $3,516 | $107 |
| Short return visit (20+ min) | 29 | $2,109 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $1,877 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,101 | $61 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 25 | $308 | $12 |
Who their Medicare patients are
264 Original Medicare patients in 2024. Average age 72 · Under 65 13% · 85 and older 8% · Women 58% · Also on Medicaid 18% · Health risk score 1.68. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Depression 42% · Diabetes 33% · Chronic kidney disease 31% · Coronary heart disease 29% · Cancer 20% · Atrial fibrillation 20% · COPD 19% · Stroke 19% · Dementia 18% · Heart failure 17%.
The office billed $898,644, Medicare allowed $292,201 and paid $227,044; for 35,288 services of 37 kinds; $172,785 of it was for drugs given in the office and $54,259 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 264 | 35,288 | 72 | 1.68 | $898,644 | $227,044 |
| 2023 | 294 | 26,669 | 71 | 1.68 | $744,378 | $185,616 |
| 2022 | 263 | 27,388 | 70 | 1.96 | $758,111 | $190,951 |
| 2021 | 278 | 17,237 | 70 | 1.94 | $552,866 | $141,282 |
| 2020 | 170 | 2,550 | 71 | 1.70 | $139,075 | $35,191 |
| 2019 | 40 | 59 | 72 | 1.54 | $12,280 | $7,128 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Botox | 53 | $118,375 | None |
| Return visit (30+ min) | 80 | $9,111 | $88 |
| Long return visit (40+ min) | 47 | $6,917 | $128 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 23 | $6,808 | $139 |
| Muscle electrical test | 46 | $5,114 | $58 |
| Face injection for nerve paralysis | 12 | $4,771 | $145 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,565 | $104 |
| New patient visit (60+ min) | 30 | $4,067 | $136 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 13 | $2,311 | $96 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,139 | $63 |
| Short return visit (20+ min) | 23 | $1,719 | $66 |
2022: 14 services
| Botox | 57 | $121,772 | None |
| Return visit (30+ min) | 57 | $7,407 | $87 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 23 | $7,108 | $145 |
| Long return visit (40+ min) | 45 | $6,176 | $126 |
| New patient visit (60+ min) | 37 | $5,360 | $145 |
| Muscle electrical test | 41 | $5,187 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,311 | $158 |
| Face injection for nerve paralysis | 12 | $2,632 | $125 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 13 | $2,203 | $105 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,933 | $107 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $1,746 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,468 | $56 |
| Short return visit (20+ min) | 14 | $1,102 | $69 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $651 | $31 |
2021: 13 services
| Botox | 55 | $81,846 | None |
| New patient visit (60+ min) | 70 | $10,798 | $154 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 33 | $7,459 | $84 |
| Return visit (30+ min) | 59 | $6,854 | $97 |
| Long return visit (40+ min) | 40 | $6,313 | $134 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 22 | $4,347 | $124 |
| Muscle electrical test | 41 | $3,975 | $63 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,740 | $163 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 15 | $2,669 | $111 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $1,883 | $94 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 12 | $1,496 | $93 |
| Face injection for nerve paralysis | 12 | $1,476 | $114 |
| Short return visit (20+ min) | 11 | $714 | $60 |
2020: 8 services
| Botox | 11 | $10,211 | None |
| New patient visit (60+ min) | 34 | $5,456 | $160 |
| Return visit (30+ min) | 24 | $2,200 | $85 |
| Long return visit (40+ min) | 18 | $1,896 | $105 |
| New patient visit (45+ min) | 18 | $1,856 | $103 |
| New patient visit (60+ min) | 14 | $1,200 | $86 |
| Return visit (30+ min) | 11 | $781 | $65 |
| Muscle electrical test | 11 | $616 | $56 |
2019: 2 services
| New patient visit (60+ min) | 25 | $3,752 | $150 |
| Long return visit (40+ min) | 14 | $1,691 | $99 |
Medicaid work
$7,823 in 2021
Medicaid paid $7,823 for 24 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Botox | 24 | $7,823 |
| 2021 | 24 | 1 | 12 | $7,823 |
Drugs they prescribed that Part D paid
$279,433
Pharmacies billed $279,433 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (35 of 877) in 2024. A higher opioid share than 9 in 10 peers; the typical neurology clinician is at 0%.
823 generic and 54 brand-name prescriptions · $279,433 in drug cost · 50 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ingrezza | 12 | $97,452 | $8,121 |
| Austedo | 11 | $45,696 | $4,154 |
| Carbidopa-Levodopa | 167 | $6,472 | $39 |
| Carbidopa-Levodopa Er | 73 | $4,959 | $68 |
| Amantadine | 27 | $1,876 | $69 |
See all 22 drugs
| Ingrezza | 12 | $97,452 | $8,121 |
| Austedo | 11 | $45,696 | $4,154 |
| Carbidopa-Levodopa | 167 | $6,472 | $39 |
| Carbidopa-Levodopa Er | 73 | $4,959 | $68 |
| Amantadine | 27 | $1,876 | $69 |
| Clozapine | 38 | $1,342 | $35 |
| Baclofen | 43 | $1,082 | $25 |
| Clonazepam | 43 | $830 | $19 |
| Atropine Sulfate | 16 | $786 | $49 |
| Gabapentin | 28 | $744 | $27 |
| Propranolol Hcl Er | 27 | $721 | $27 |
| Primidone | 13 | $514 | $40 |
| Pregabalin | 21 | $427 | $20 |
| Ropinirole | 23 | $392 | $17 |
| Pramipexole Dihydrochloride | 19 | $292 | $15 |
| Lorazepam | 25 | $274 | $11 |
| Levetiracetam | 15 | $262 | $17 |
| Lamotrigine | 11 | $141 | $13 |
| Donepezil | 13 | $111 | $9 |
| Trihexyphenidyl | 11 | $91 | $8 |
| Tramadol | 30 | $72 | $2 |
| Sertraline | 15 | $70 | $5 |
Year by year
| 2024 | 877 | 149 | 4% (35) | 6% | $279,433 |
| 2023 | 546 | 106 | None | 7% | $225,940 |
| 2022 | 343 | 76 | 3% (11) | 8% | $63,566 |
| 2021 | 264 | 65 | 5% (12) | None | $21,597 |
| 2020 | 125 | 39 | 0% (0) | None | $29,986 |
| 2019 | 70 | 21 | 0% (0) | None | $5,236 |
| 2018 | 141 | 22 | 0% (0) | None | $7,355 |
| 2017 | 253 | 36 | 0% (0) | None | $77,564 |
| 2016 | 257 | 38 | None | None | $20,903 |
| 2015 | 128 | 29 | None | None | $3,219 |
| 2014 | 13 | None | 0% (0) | None | $93 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Ingrezza | 16 | $130,685 | $8,168 |
| Carbidopa-Levodopa | 87 | $3,657 | $42 |
| Clozapine | 87 | $2,121 | $24 |
| Carbidopa-Levodopa Er | 27 | $1,995 | $74 |
| Amantadine | 14 | $1,366 | $98 |
| Topiramate | 11 | $602 | $55 |
| Gabapentin | 42 | $567 | $13 |
| Baclofen | 29 | $544 | $19 |
| Pramipexole Dihydrochloride | 20 | $539 | $27 |
| Levetiracetam | 13 | $490 | $38 |
| Pregabalin | 13 | $379 | $29 |
| Lorazepam | 13 | $169 | $13 |
| Cyclobenzaprine | 17 | $142 | $8 |
2022: 9 drugs
| Rytary | Parkinson's | 13 | $14,425 | $1,110 |
| Carbidopa-Levodopa | None | 49 | $1,860 | $38 |
| Amantadine | None | 12 | $1,125 | $94 |
| Carbidopa-Levodopa Er | None | 24 | $705 | $29 |
| Gabapentin | None | 36 | $656 | $18 |
| Clonazepam | None | 12 | $345 | $29 |
| Benztropine Mesylate | None | 12 | $237 | $20 |
| Clozapine | None | 12 | $149 | $12 |
| Lorazepam | None | 11 | $84 | $8 |
2021: 5 drugs
| Carbidopa-Levodopa | 52 | $3,831 | $74 |
| Gabapentin | 19 | $164 | $9 |
| Lorazepam | 12 | $107 | $9 |
| Trazodone | 14 | $90 | $6 |
| Tramadol | 12 | $51 | $4 |
2020: 2 drugs
| Carbidopa-Levodopa | 51 | $1,719 | $34 |
| Gabapentin | 17 | $178 | $10 |
2019: 1 drug
| Carbidopa-Levodopa | 24 | $394 | $16 |
2018: 4 drugs
| Levetiracetam | 20 | $556 | $28 |
| Baclofen | 11 | $376 | $34 |
| Topiramate | 12 | $131 | $11 |
| Amitriptyline | 15 | $119 | $8 |
2017: 6 drugs
| Divalproex Sodium Er | 12 | $2,762 | $230 |
| Levetiracetam | 17 | $482 | $28 |
| Atorvastatin | 11 | $224 | $20 |
| Amitriptyline | 25 | $160 | $6 |
| Gabapentin | 15 | $157 | $10 |
| Divalproex | 16 | $107 | $7 |
2016: 3 drugs
| Atorvastatin | 29 | $394 | $14 |
| Levetiracetam | 21 | $307 | $15 |
| Amlodipine Besylate | 16 | $94 | $6 |
2015: 2 drugs
| Metoprolol | 19 | $403 | $21 |
| Warfarin | 12 | $68 | $6 |
Money from drug and device companies
$2,986 in 2022
| 2022 | 1 | 22 | None | $2,986 |
| 2019 | 2 | 19 | None | $45,080 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Percept PC Brainsense | $2,986 | 22 payments
|
See all 22 published payments
| Medtronic | Travel · 2022-07-22 | Percept PC Brainsense | $867 |
| Medtronic | Travel · 2022-07-22 | Percept PC Brainsense | $87 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $15 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $45 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $75 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $6 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $87 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $47 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $82 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $11 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $8 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $11 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $12 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $95 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $170 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $29 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $94 |
| Medtronic | Meals · 2022-07-22 | Percept PC Brainsense | $43 |
| Medtronic | Travel · 2022-06-08 | Percept PC Brainsense | $55 |
| Medtronic | Travel · 2022-05-10 | Percept PC Brainsense | $30 |
| Medtronic | Travel · 2022-03-24 | Percept PC Brainsense | $1,089 |
| Medtronic | Travel · 2022-03-24 | Percept PC Brainsense | $30 |
See earlier years (2019)
2019: $45,080
| Medtronic USA | Activa | $44,790 | 16 payments
|
| Boston Scientific | Spectra Wavewriter | $290 | 3 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 78.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1477968451
- Licence
- SC LL37086
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2014-06-27
- NPI last updated
- 2019-05-03
This is when the NPI record was last certified, not a medical board exam.